Valuation: AstraZeneca PLC

Market Cap 262B 230B 214B 197B 369B 25,249B 375B 2,543B 994B 12,413B 984B 963B 42,919B P/E 2026 *
21.1x
P/E 2027 * 18.5x
Enterprise Value 281B 247B 230B 211B 396B 27,097B 402B 2,729B 1,066B 13,322B 1,056B 1,034B 46,061B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 4.1x
Free-Float
96.63%
Yield 2026 *
1.98%
Yield 2027 * 2.08%

Last Transcript: AstraZeneca PLC

1 day+0.59%
Current month+82.45%
6 months+79.62%
Current year+84.12%
Current year 89.04
Extreme 89.04
170.26
1 year 71.49
Extreme 71.49
170.26
3 years 60.47
Extreme 60.47
170.26
5 years 52.65
Extreme 52.65
170.26
10 years 25.55
Extreme 25.55
170.26
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%+0.21% - - 262B
+0.86%+1.43%+48.50%+160.39% 1,057B
+1.59%+4.09%+55.34%+53.96% 624B
+0.95%+1.91%+35.91%+81.14% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
+0.09%-2.82%-28.29%-41.71% 215B
+1.22%+2.66%+21.87%+59.73% 201B
-1.18%-3.70%+14.23%+66.51% 162B
-0.16%-2.04%-3.20%-34.58% 143B
Average +0.38%+0.97%+23.78%+46.12% 388.29B
Weighted average by Cap. +0.56%+1.85%+35.61%+77.54%

Financials

2026 *2027 *
Net sales 63.21B 55.51B 51.63B 47.37B 89.01B 6,087B 90.38B 613B 240B 2,992B 237B 232B 10,346B 66.78B 58.65B 54.54B 50.05B 94.04B 6,431B 95.49B 648B 253B 3,162B 251B 245B 10,931B
Net income 12.43B 10.92B 10.15B 9.32B 17.51B 1,197B 17.78B 121B 47.11B 589B 46.67B 45.66B 2,035B 13.93B 12.23B 11.38B 10.44B 19.62B 1,341B 19.92B 135B 52.78B 659B 52.29B 51.16B 2,280B
Net Debt 19.2B 16.86B 15.68B 14.39B 27.03B 1,849B 27.45B 186B 72.74B 909B 72.06B 70.51B 3,142B 11.9B 10.45B 9.72B 8.92B 16.76B 1,146B 17.02B 115B 45.1B 564B 44.68B 43.72B 1,948B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
24/07/26 US$169.26 +0.59% 2,009,993
23/07/26 US$168.27 -0.86% 2,394,069
22/07/26 US$169.73 +0.23% 1,683,823
21/07/26 US$169.34 +2.93% 1,986,357
20/07/26 US$164.52 -2.59% 2,552,981
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
169.04USD
Average target price
212.16USD
Spread / Average Target
+25.51%

Quarterly revenue - Rate of surprise